Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma

In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1. Dendritic cell-based immunotherapy (DC vaccine alone or DC vaccine plus lym...

Full description

Saved in:

Bibliographic Details
Published in:	Pancreas Vol. 41; no. 2; pp. 195 - 205
Main Authors:	Kimura, Yukino, Tsukada, Jun, Tomoda, Takeshi, Takahashi, Hidenori, Imai, Kazuhiro, Shimamura, Kanae, Sunamura, Makoto, Yonemitsu, Yoshikazu, Shimodaira, Shigetaka, Koido, Shigeo, Homma, Sadamu, Okamoto, Masato
Format:	Journal Article
Language:	English
Published:	United States 01-03-2012
Subjects:	Adult Aged Aged, 80 and over Analysis of Variance Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Vaccines - adverse effects Cancer Vaccines - therapeutic use Carcinoma - diagnosis Carcinoma - drug therapy Carcinoma - immunology Carcinoma - mortality Carcinoma - therapy Chemotherapy, Adjuvant Dendritic Cells - immunology Dendritic Cells - transplantation Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Combinations Female Humans Japan Kaplan-Meier Estimate Killer Cells, Lymphokine-Activated - immunology Killer Cells, Lymphokine-Activated - transplantation Male Middle Aged Multimodal Imaging Oxonic Acid - administration & dosage Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - immunology Pancreatic Neoplasms - mortality Pancreatic Neoplasms - therapy Positron-Emission Tomography Retrospective Studies T-Lymphocytes, Cytotoxic - drug effects T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - immunology Tegafur - administration & dosage Time Factors Tomography, X-Ray Computed Treatment Outcome Japan
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1. Dendritic cell-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer [LAK] cell therapy) in combination with gemcitabine and/or S-1 has been carried out in 49 patients with inoperable pancreatic carcinoma refractory to standard treatment. Of 49 patients, 2 patients had complete remission, 5 had partial remission, and 10 had stable disease. Prolongation of survival in this cohort was highly likely (median survival, 360 days). Survival of patients receiving DC vaccine and chemotherapy plus LAK cell therapy was longer than those receiving DC vaccine in combination with chemotherapy but no LAK cells. Increased numbers of cancer antigen-specific cytotoxic T cells and decreased regulatory T cells were observed in several patients on immunotherapy, but increased overall survival time tended to be associated only with the latter. None of the patients experienced grade 3 or worse adverse events during the treatment period. Dendritic cell vaccine-based immunotherapy combined with chemotherapy was shown to be safe and possibly effective in patients with advanced pancreatic cancer refractory to standard treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0885-3177 1536-4828
DOI:	10.1097/MPA.0b013e31822398c6